Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Oncol. Apr 15, 2013; 5(4): 71-80
Published online Apr 15, 2013. doi: 10.4251/wjgo.v5.i4.71
Published online Apr 15, 2013. doi: 10.4251/wjgo.v5.i4.71
Ref. | Patients (tumors) n | Method | Mean tumor size (cm) | RCC | Complete first ablation | Recurrence free survival | Overall survival (yr) | Cancer specific survival (yr) | Complications | |||
1 | 3 | 5 | 3 | 5 | ||||||||
Tracy et al[69] | 208 (243) | P, L, O | 2.4 | 79% | 97% | 90% at 3 yr2 | 99%1 | 93%1 | 85% | 95% for RCC | 99% for RCC | NR |
Levinson et al[70] | 31 (34) | P, L | 2.1 | 58% | 91% | 80% at 5 yr2 | NR | NR | 63% for all358% for RCC4 | NR | 100% for all 100% for RCC | 4 for perinephric hematoma ; 1 for liver burn; 1 for death from pneumonia |
Zagoria et al[71] | 41 (48) | P | 2.6 | 100% | NR | 88% at 5 yr | NR | NR | 66% | NR | NR | 2 for pneumothorax no drainage; 2 for ureteral strictures |
Stern et al[72] | 40 | P, L | 2.4 | 81% | 97% | 91% at 3 yr2 | NR | NR | NR | 100% for RCC | NR | 2 for minor; 3 for major |
- Citation: Shah DR, Green S, Elliot A, McGahan JP, Khatri VP. Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol 2013; 5(4): 71-80
- URL: https://www.wjgnet.com/1948-5204/full/v5/i4/71.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v5.i4.71